These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37817570)

  • 1. Is imiquimod a promising drug to treat oral mucosa diseases? A scoping review and new perspectives.
    de Mello Palma V; Frank LA; Balinha DM; Rados PV; Pohlmann AR; Guterres SS; Visioli F
    Br J Clin Pharmacol; 2024 Feb; 90(2):427-439. PubMed ID: 37817570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How safe is off-label use of imiquimod in oral lesions?
    Amaral AL; Lwaleed BA; Bouquot JE; Andrade SA
    Evid Based Dent; 2024 Jun; ():. PubMed ID: 38867102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
    Bhatta AK; Wang P; Keyal U; Zhao Z; Ji J; Zhu L; Wang X; Zhang G
    Photodiagnosis Photodyn Ther; 2018 Sep; 23():273-280. PubMed ID: 30030167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microneedles for oral mucosal delivery - Current trends and perspective on future directions.
    Ferreira LEN; Franz-Montan M; Benso B; Gill HS
    Expert Opin Drug Deliv; 2023; 20(9):1251-1265. PubMed ID: 37781735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod Exerts Antitumor Effects by Inducing Immunogenic Cell Death and Is Enhanced by the Glycolytic Inhibitor 2-Deoxyglucose.
    Huang SW; Wang ST; Chang SH; Chuang KC; Wang HY; Kao JK; Liang SM; Wu CY; Kao SH; Chen YJ; Shieh JJ
    J Invest Dermatol; 2020 Sep; 140(9):1771-1783.e6. PubMed ID: 32035924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-assembled mPEG-hexPLA polymeric nanocarriers for the targeted cutaneous delivery of imiquimod.
    Lapteva M; Mignot M; Mondon K; Möller M; Gurny R; Kalia YN
    Eur J Pharm Biopharm; 2019 Sep; 142():553-562. PubMed ID: 30641138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microemulsions based on TPGS and isostearic acid for imiquimod formulation and skin delivery.
    Pescina S; Garrastazu G; Del Favero E; Rondelli V; Cantù L; Padula C; Santi P; Nicoli S
    Eur J Pharm Sci; 2018 Dec; 125():223-231. PubMed ID: 30316975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod Accelerated Antitumor Response by Targeting Lysosome Adaptation in Skin Cancer Cells.
    Chang SH; Wu CY; Chuang KC; Huang SW; Li ZY; Wang ST; Lai ZL; Chang CC; Chen YJ; Wong TW; Kao JK; Shieh JJ
    J Invest Dermatol; 2021 Sep; 141(9):2219-2228.e8. PubMed ID: 33744296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local drug delivery for oral mucosal diseases: challenges and opportunities.
    Sankar V; Hearnden V; Hull K; Juras DV; Greenberg MS; Kerr AR; Lockhart PB; Patton LL; Porter S; Thornhill M
    Oral Dis; 2011 Apr; 17 Suppl 1():73-84. PubMed ID: 21382140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2.
    Hao Y; Peng B; Che D; Zheng Y; Kong S; Liu R; Shi J; Han H; Wang J; Cao J; Zhang Y; Gao J; He L; Geng S
    Int Immunopharmacol; 2020 Apr; 81():106258. PubMed ID: 32044660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
    Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
    Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature.
    Hammerl V; Parlar B; Navarini A; Gantenbein L; Väth H; Mueller SM
    Dermatol Ther; 2021 Jan; 34(1):e14355. PubMed ID: 32990395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local delivery of imiquimod in hamsters using mucoadhesive films and their residence time in human patients.
    Ramineni SK; Dziubla TD; Cunningham LL; Puleo DA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Dec; 118(6):665-73. PubMed ID: 25457885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer.
    Singh B; Maharjan S; Pan DC; Zhao Z; Gao Y; Zhang YS; Mitragotri S
    Biomaterials; 2022 Jan; 280():121302. PubMed ID: 34894584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of topical drugs in treatment of oral mucosal diseases. A literature review.
    Sheikh S; Gupta D; Pallagatti S; Singla I; Gupta R; Goel V
    N Y State Dent J; 2013 Nov; 79(6):58-64. PubMed ID: 24600767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments and opportunities in oral mucosal drug delivery for local and systemic disease.
    Hearnden V; Sankar V; Hull K; Juras DV; Greenberg M; Kerr AR; Lockhart PB; Patton LL; Porter S; Thornhill MH
    Adv Drug Deliv Rev; 2012 Jan; 64(1):16-28. PubMed ID: 21371513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial.
    Polterauer S; Reich O; Widschwendter A; Hadjari L; Bogner G; Reinthaller A; Joura E; Trutnovsky G; Ciresa-Koenig A; Ganhoer-Schimboeck J; Boehm I; Berger R; Langthaler E; Aberle SW; Heinze G; Gleiss A; Grimm C
    Gynecol Oncol; 2022 Apr; 165(1):23-29. PubMed ID: 35177279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-functional drug delivery nanosystem release of TLR-7 immunostimulant and OKT3 induced efficient cancer immunotherapy.
    Li R; Huang X; Li X; Liu H; Zhou J; Shen J
    Photodiagnosis Photodyn Ther; 2023 Dec; 44():103834. PubMed ID: 37802276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod-enhanced immunotherapy with diphencyprone for patients with alopecia areata.
    Díaz-Guimaraens B; Saceda-Corralo D; Hermosa-Gelbard Á; Moreno-Arrones ÓM; Dominguez-Santas M; Suarez-Valle A; Vañó-Galván S
    Dermatol Ther; 2022 Jul; 35(7):e15516. PubMed ID: 35421278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of hyperbranched core-multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa.
    Jager J; Obst K; Lohan SB; Viktorov J; Staufenbiel S; Renz H; Unbehauen M; Haag R; Hedtrich S; Teutloff C; Meinke MC; Danker K; Dommisch H
    J Periodontal Res; 2018 Feb; 53(1):57-65. PubMed ID: 28898420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.